{"id":1323415,"date":"2026-11-19T15:22:20","date_gmt":"2026-11-19T15:22:20","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/1323415\/"},"modified":"2026-11-19T15:22:20","modified_gmt":"2026-11-19T15:22:20","slug":"glp-1-pill-and-men-drives-weight-loss-drug-boom-in-great-britain","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/1323415\/","title":{"rendered":"GLP-1 pill and men drives weight-loss drug boom in Great Britain"},"content":{"rendered":"<p class=\"c-paragraph b-article-body-skinny\">The GLP-1 pill format is making its mark among users, now accounting for more than one in ten GLP-1 users in Great Britain. And it\u2019s driving rapid growth \u2013 the number of British households with at least one GLP-1 user was 8.5% in August, up from 6.3% just six months earlier, according to a new Worldpanel by Numerator report. <\/p>\n<p class=\"c-paragraph b-article-body-skinny\">\u201cWhen we began tracking GLP-1 use back in 2024, manufacturers and retailers were always asking us, is this here to stay? Should we really be concerned?\u201d says Nishita Pattni, senior consultant at Worldpanel by Numerator. \u201cFast forward two years and there has been such a boom. In the last six months, we have seen such an increase in users, as much as it took a year to increase previously.\u201d <\/p>\n<p class=\"c-paragraph b-article-body-skinny\">The arrival of the GLP-1 pill is very recent and the UK led the way in Europe \u2013 the <a href=\"https:\/\/www.foodnavigator.com\/Article\/2026\/06\/12\/wegovy-weight-loss-pill-approved-for-use-in-the-uk\/\" target=\"_blank\" rel=\"nofollow noopener\">Wegovy pill was approved in the UK<\/a> in June, the first pill to be approved in Europe. The UK was also first to approve Eli Lilly\u2019s Foundayo (orforglipron) in August. It\u2019s therefore a good indicator of the effect of the pill as it <a href=\"https:\/\/www.foodnavigator.com\/Article\/2026\/08\/06\/germany-first-to-launch-wegovy-pill\/\" target=\"_blank\" rel=\"nofollow noopener\" title=\"https:\/\/www.foodnavigator.com\/Article\/2026\/08\/06\/germany-first-to-launch-wegovy-pill\/\">launches across Europe<\/a>. <\/p>\n<p class=\"c-paragraph b-article-body-skinny\">\u201cWhen the pill format was launched this summer, we saw a huge spike, so a lot of these users are first-time users,\u201d says Pattni. \u201cAnd we saw similar spikes in the US. We only anticipate that it will grow further when we go back into the field in February, when the pill will have been around for over six months.\u201d<\/p>\n<p>Number of male users almost double<\/p>\n<p class=\"c-paragraph b-article-body-skinny\">Men are also driving growth \u2013 they now account for 32% of users, up from 23% in February. That equates to a near doubling in number at 830,000, up from 440,000. <\/p>\n<p class=\"c-paragraph b-article-body-skinny\">What accounts for this? \u201cWe\u2019ve called this latest report The Evolution Continues, and the appeal and adoption of these drugs is becoming far more mass and widespread,\u201d says Pattni. \u201cTo date, the adoption of GLP-1 drugs is not even with 68% of users being female, but the growth that has recently come in has been driven by men, which points to that mass adoption.\u201d<\/p>\n<p class=\"c-paragraph b-article-body-skinny\">We also see that a chunk of lapsers are returning to GLP-1s, she adds, so the growth is not linear. \u201cIt\u2019s still an evolving space, but every time we track this, that appeal is widening and that\u2019s where I think the men come in.\u201d<\/p>\n<p class=\"c-paragraph b-article-body-skinny\">The rise in men is a space to watch for manufacturers as they may well bring different purchasing patterns and needs. <\/p>\n<p>A \u00a31bn impact but a surprise success story <\/p>\n<p class=\"c-paragraph b-article-body-skinny\">The impact on grocery spend is now over \u00a31bn (\u20ac1.20bn), up from \u00a3780m in June, with impulse and indulgence purchases taking the biggest hit. Crisps spend, for example, has fallen 15%. Alcohol is also suffering \u2013 spend among GLP-1 users has fallen 15% more than in non-user households. <\/p>\n<p class=\"c-paragraph b-article-body-skinny\">The overall drop equates to \u00a3389 a year displaced from user households\u2019 shopping baskets.<\/p>\n<p class=\"c-paragraph b-article-body-skinny\">Convenient formats continue to do well and frozen ready meals saw a 30% uplift in volume. However, there was a surprise success story. Hot chocolate and malt drinks were up 22% in spend and 16% in volume. <\/p>\n<p class=\"c-paragraph b-article-body-skinny\">\u201cIt was one of the most surprising growth categories for us,\u201d says Pattni. Along with being a permissible, more lightweight treat, there are a few different theories behind it, she says. \u201cFirstly, we know that users have less disposable income since starting on GLP-1s and hot chocolate and malt drinks are an affordable, accessible treat. Secondly, some users report heightened sensitivity to stimulants, and we\u2019ve seen the likes of energy drinks and instant coffee struggling. Hot chocolate feels like a treat but it\u2019s not overly stimulating.\u201d<\/p>\n<p>More growth is on the horizon <\/p>\n<p class=\"c-paragraph b-article-body-skinny\">\u201cWe were not surprised by the acceleration in users and the drop in spend,\u201d says Pattni. \u201cWe\u2019ve been trying to tell everyone that this is here to stay and we are very confident that this will only grow.\u201d<\/p>\n<p class=\"c-paragraph b-article-body-skinny\">Worldpanel forecasts that GLP-1 usage is set to surpass 10% of Great Britain\u2019s households in 2027. \u201cA lot of our forecast is based on users remaining satisfied, considerers gaining confidence, and various events all falling into place,\u201d says Pattni, \u201cbut even our most conservative estimates place it above 10%.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"The GLP-1 pill format is making its mark among users, now accounting for more than one in ten&hellip;\n","protected":false},"author":2,"featured_media":1323416,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[5018,3,4],"tags":[42374,355012,1298,748,17838,6442,393,10709,190126,16231,355013,4884,105,4348,2837,355014,114286,4554,48998,355015,1144,355016,370,5485,355017,50174,140653,712,16369,1408,16,15,1764],"class_list":["post-1323415","post","type-post","status-publish","format-standard","has-post-thumbnail","category-britain","category-uk","category-united-kingdom","tag-ball","tag-bauble","tag-blood-sugar","tag-britain","tag-chronic","tag-endocrinology","tag-england","tag-fat","tag-festive","tag-glp-1","tag-glucagonlikepeptide1","tag-great-britain","tag-health","tag-healthcare","tag-holiday","tag-injector","tag-isolated","tag-medical","tag-metabolic","tag-new-year-treatment","tag-northern-ireland","tag-ornament","tag-ozempic","tag-pharmaceutical","tag-post-holiday","tag-reset","tag-resolution","tag-scotland","tag-slimming","tag-therapy","tag-uk","tag-united-kingdom","tag-wales"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/117643794326877600","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1323415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=1323415"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1323415\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/1323416"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=1323415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=1323415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=1323415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}